Thorax vs. Trauma Injury Severity Scores as Outcome Predictors in Chest Trauma
ConditionChest Trauma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16+
SponsorAl-Nahrain University
About this trial
The goal of this observational study is to compare the predictive utility of the Thorax Trauma Severity Score (TTSS) and the Trauma and Injury Severity Score (TRISS) in determining outcomes among patients presenting with chest trauma to the emergency room. The main questions it aims to answer are:
Does the TTSS provide a more accurate prediction of patient outcomes (e.g., mortality, ICU admission) than the TRISS? Are there specific patient subgroups where one score is more effective than the other?
Participants will:
Have their chest trauma severity assessed using both TTSS and TRISS during their emergency room admission.
Have their clinical outcomes (e.g., mortality, ICU admission, length of hospital stay) monitored throughout their hospital stay.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with chest injuries that require clinical assessment using the Thorax Trauma Severity Score (TTSS) and the Trauma Injury Severity Score (TISS) within 6 hours of admission.
Patients (or their legal guardians) must provide informed consent for participation in the study. This ensures ethical standards are maintained.
Patients presenting with thoracic injuries, including rib fractures, pulmonary contusions, pneumothorax, hemothorax, and other chest-related injuries. This will include both isolated chest trauma and trauma with multiple injuries
Disqualifiers
Patients younger than 16 years.
Patients with chest injuries caused by conditions unrelated to trauma, such as spontaneous pneumothorax, infections, or other medical conditions (e.g., non-traumatic rib fractures or cancer).
Patients with severe co-morbidities (e.g., terminal illnesses, advanced stages of cancer, or end-stage organ failure) that would significantly affect outcomes unrelated to the chest trauma.
Patients with pre-existing severe neurological conditions or other comorbidities that would interfere with trauma assessment and clinical management (e.g., severe brain injury, vegetative state).
Trial population
The study population will consist of adult patients (18 years and older) who present to the Emergency Department (ER) of Al-Kadhimiya Teaching Hospital with chest trauma. This population will be classified based on the severity of their injuries, ranging from minor to critical, and include both blunt and penetrating trauma cases.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
In hospital mortality
Mortality (death) during hospitalization.
Time frame
In-Hospital Phase (average of 7-10 days through discharge)2
Accuracy Assessment of Thorax Trauma Severity Score (TTSS)
Range: from 0 to 25, with higher scores indicating more severe thoracic trauma.
Time frame
the first 6 hours after ER admission3
Accuracy Assessment of Trauma and Injury Severity Score (TRISS)
Range: 0 (represents a 0% probability of survival) to 1 (represents a 100% probability of survival), with higher scores indicating greater trauma severity.
Time frame
the first 6 hours after ER admissionSecondary outcomes
1
Length of Hospitalization
Description: The total duration of a patient's stay in the hospital, measured from the date of admission to the date of discharge. This includes all days spent in general wards, intensive care units (ICU), and other hospital departments as part of their treatment course.
Time frame
Up to discharge, an average of 7-10 days2
Rate of admission to the intensive care unit (ICU)
The requirement for admission to the intensive care unit (ICU) is determined by the presence of severe clinical deterioration, significant complications, or the need for advanced monitoring and life-support measures.
Time frame
Up to discharge, an average of 7-10 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov